WHO Sounds Warning Over Critical Lack of Obesity Medications
Fewer than a tenth of individuals that would benefit from weight-loss injections like Wegovy can access them, warns the World Health Organization as it issues its initial recommendations on the therapies.
Considering over a billion individuals worldwide now classified as obese, it is calling for increased and just access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our latest guidance affirms that excess weight is a chronic disease that can be managed with comprehensive and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are key hurdles to broad availability to the treatments that can help people shift considerable weight, says the organization.
Skinny Jab Scarcity
Despite the present best projected case, the production of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, according to the WHO.
The advice calls on countries and companies to widen access, by approaches like patent sharing.
Exclusive production rights on semaglutide – the core component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
How Obesity Jabs Work
These medications imitate a natural hormone to slow digestion, reduce hunger and boost feelings of fullness so individuals reduce food intake.
Individuals commonly begin shedding pounds within a few weeks of starting on the weekly injections.
Studies points to users may put most of the weight back on after a year of discontinuing the drug, because their typical hunger come back.
Being carrying excess weight elevates your chance for developing medical conditions, like type 2 diabetes, heart disease, brain attack, and certain malignancies.
Obesity affects people in every country and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.
